PMID- 25239811
OWN - NLM
STAT- MEDLINE
DCOM- 20150803
LR  - 20141201
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 23
IP  - 2
DP  - 2014 Dec
TI  - Non-mitogenic form of acidic fibroblast growth factor protects against 
      graft-versus-host disease without accelerating leukemia.
PG  - 395-9
LID - S1567-5769(14)00347-6 [pii]
LID - 10.1016/j.intimp.2014.09.006 [doi]
AB  - Acid fibroblast growth factor (aFGF) has been shown to prevent epithelial damage 
      under various conditions, suggesting its potential to inhibit GVHD. However, 
      because aFGF receptors are expressed on tumor cells, it may possibly offset the 
      graft-vs.-tumor (GVT) effects of allogeneic bone marrow transplantation 
      (allo-BMT). Here, we addressed these questions in a B6-->B6D2F1 allo-BMT model. 
      Although aFGF administration attenuated GVHD in non-leukemic recipients, aFGF 
      treatment markedly accelerated death in mice that received recipient-type tumor 
      (P815) cells along with allo- or syngeneic-BMT. Similar protection against GVHD 
      was achieved by administration of a non-mitogenic form of aFGF (naFGF). 
      Importantly, GVT effects were fully preserved in naFGF-treated recipients. 
      Furthermore, aFGF, but not naFGF, significantly enhanced P815 cell proliferation 
      both in vitro and in vivo. Our data indicate that the tumor-promoting, but not 
      GVHD-protecting, effect of aFGF largely depends on its mitogenic activity, and 
      suggest that naFGF may provide a safer approach to inhibiting GVHD in patients 
      with malignancies.
CI  - Copyright (c) 2014 Elsevier B.V. All rights reserved.
FAU - Wang, Yi
AU  - Wang Y
AD  - Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou 
      Medical University, Wenzhou 325035, PR China; Transplantation Biology Research 
      Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, 
      USA.
FAU - Wang, Hui
AU  - Wang H
AD  - Transplantation Biology Research Center, Massachusetts General Hospital, Harvard 
      Medical School, Boston, MA 02129, USA; Columbia Center for Translational 
      Immunology, Columbia University Medical Center, New York, NY, USA.
FAU - Ren, Luqing
AU  - Ren L
AD  - Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou 
      Medical University, Wenzhou 325035, PR China.
FAU - Weng, Qiaoyou
AU  - Weng Q
AD  - Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou 
      Medical University, Wenzhou 325035, PR China.
FAU - Bao, Yuyan
AU  - Bao Y
AD  - Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou 
      Medical University, Wenzhou 325035, PR China.
FAU - Tian, Haishan
AU  - Tian H
AD  - Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou 
      Medical University, Wenzhou 325035, PR China.
FAU - Yang, Yong-Guang
AU  - Yang YG
AD  - Transplantation Biology Research Center, Massachusetts General Hospital, Harvard 
      Medical School, Boston, MA 02129, USA; Columbia Center for Translational 
      Immunology, Columbia University Medical Center, New York, NY, USA; First Hospital 
      of Jilin University, Changchun, PR China. Electronic address: 
      yy2324@cumc.columbia.edu.
FAU - Li, Xiaokun
AU  - Li X
AD  - Key Laboratory of Biotechnology Pharmaceutical Engineering, School of 
      Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, PR China. 
      Electronic address: proflxk@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140916
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 104781-85-3 (Fibroblast Growth Factor 1)
SB  - IM
MH  - Animals
MH  - Bone Marrow Transplantation/*adverse effects
MH  - Cell Line
MH  - Cell Proliferation
MH  - Fibroblast Growth Factor 1/*administration & dosage
MH  - Graft vs Host Disease/*prevention & control
MH  - Humans
MH  - Leukemia/*pathology
MH  - Mice
OTO - NOTNLM
OT  - Acidic fibroblast growth factor
OT  - GVHD
OT  - GVL
OT  - Mitogenic activity
EDAT- 2014/09/23 06:00
MHDA- 2015/08/04 06:00
CRDT- 2014/09/21 06:00
PHST- 2014/03/25 00:00 [received]
PHST- 2014/08/13 00:00 [revised]
PHST- 2014/09/05 00:00 [accepted]
PHST- 2014/09/21 06:00 [entrez]
PHST- 2014/09/23 06:00 [pubmed]
PHST- 2015/08/04 06:00 [medline]
AID - S1567-5769(14)00347-6 [pii]
AID - 10.1016/j.intimp.2014.09.006 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2014 Dec;23(2):395-9. doi: 10.1016/j.intimp.2014.09.006. 
      Epub 2014 Sep 16.